公开(公告)号：EP2668162A1

公开(公告)日：2013-12-04

申请号：EP12700840.7

申请日：2012-01-20

申请人： Novartis AG

发明人： ANTONIOS-MCCREA, William R. ,  BARSANTI, Paul A. ,  HU, Cheng ,  JIN, Xianming ,  MARTIN, Eric J. ,  PAN, Yue ,  LIN, Xiaodong ,  PFISTER, Keith B. ,  RENHOWE, Paul A. ,  SENDZIK, Martin ,  SUTTON, James ,  WAN, Lifeng

IPC分类号： C07D213/74 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D491/107 ,  A61K31/444 ,  A61K31/505 ,  A61K31/553 ,  A61P35/00 ,  A61P29/00 ,  A61P9/00 ,  A61P37/00 ,  A61P31/18

CPC分类号： C07D401/14 ,  C07D213/74 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/04 ,  C07D491/107

摘要： The present invention provides a compound of formula (II): where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancers and other conditions described herein.